BiotechMainstream pharmaceutical picks are out of reach for most bargain investors, making the innovative biotech market a great place to look for the next best deal. Aileron Therapeutics Inc. (NASDAQ: ALRN) is a clinical-stage biotech company that focuses on the research, development, and commercialization of novel therapeutics for cancer and other diseases.

This company is currently focusing on promising cell-permeation drugs that can suppress tumors in some forms of cancer. Late-stage trials are positive, hinting at an upside once commercialization is possible. While it’s yet to generate revenue, the company is well-funded with $28.12 million in total assets, including $18.3 million in cash and short term investments. Total liabilities are $12.07 million.

Net financing cash flow was reported at $23.59 million at the end of last year.

Analysts are confident that this stock will hit a target price of $5 in 2020, especially considering the current bullish activity in the wider stock market. This stock has growth potential and the company has long term viability with its novel cancer treatments. This is an excellent pick for a bargain portfolio.

Key Data:

  • 1 Year Price Growth: 41%
  • YTD Price Growth: 93%
  • 3 Month Price Growth: 17%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.